Monopar Therapeutics (MNPR) Liabilities and Shareholders Equity (2016 - 2025)
Quarterly results put Liabilities and Shareholders Equity at $140.7 million for Q4 2025, up 133.4% from a year ago — trailing twelve months through Dec 2025 was $393.9 million (up 377.69% YoY), and the annual figure for FY2025 was $140.7 million, up 133.4%.
Monopar Therapeutics has reported Liabilities and Shareholders Equity over the past 10 years, most recently at $140.7 million for Q4 2025.
- Liabilities and Shareholders Equity reached $140.7 million in Q4 2025 per MNPR's latest filing, down from $144.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $144.2 million in Q3 2025 and bottomed at $6.1 million in Q3 2024.
- Median Liabilities and Shareholders Equity over the past 5 years was $17.4 million (2022), compared with a mean of $33.5 million.
- The largest annual shift saw Liabilities and Shareholders Equity plummeted 44.47% in 2023 before it soared 2275.71% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $20.5 million in 2021, then tumbled by 35.55% to $13.2 million in 2022, then crashed by 44.47% to $7.3 million in 2023, then soared by 720.83% to $60.3 million in 2024, then surged by 133.4% to $140.7 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for MNPR at $140.7 million in Q4 2025, $144.2 million in Q3 2025, and $53.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 40.87 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 23.64 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | 140.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 140.72 Mn |
| Sep 30, 2025 | 144.20 Mn |
| Jun 30, 2025 | 53.87 Mn |
| Mar 31, 2025 | 55.09 Mn |
| Dec 31, 2024 | 60.29 Mn |
| Sep 30, 2024 | 6.07 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Mar 31, 2024 | 8.91 Mn |
| Dec 31, 2023 | 7.35 Mn |
| Sep 30, 2023 | 8.59 Mn |
| Jun 30, 2023 | 10.34 Mn |
| Mar 31, 2023 | 11.83 Mn |
| Dec 31, 2022 | 13.23 Mn |
| Sep 30, 2022 | 14.45 Mn |
| Jun 30, 2022 | 16.74 Mn |
| Mar 31, 2022 | 18.07 Mn |
| Dec 31, 2021 | 20.52 Mn |
| Sep 30, 2021 | 22.52 Mn |
| Jun 30, 2021 | 24.46 Mn |
| Mar 31, 2021 | 25.91 Mn |
| Dec 31, 2020 | 16.87 Mn |
| Sep 30, 2020 | 18.16 Mn |
| Jun 30, 2020 | 12.80 Mn |
| Mar 31, 2020 | 12.84 Mn |
| Dec 31, 2019 | 13.35 Mn |
| Sep 30, 2019 | 5.11 Mn |
| Jun 30, 2019 | 5.60 Mn |
| Mar 31, 2019 | 6.35 Mn |
| Dec 31, 2018 | 7.32 Mn |
| Sep 30, 2018 | 7.89 Mn |
| Jun 30, 2018 | 8.45 Mn |
| Mar 31, 2018 | 9.15 Mn |
| Dec 31, 2017 | 9.93 Mn |
| Dec 31, 2016 | 2.90 Mn |